LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

Search

Iovance Biotherapeutics Inc

Abierto

SectorSalud

2.23 1.36

Resumen

Variación precio

24h

Actual

Mínimo

2.2

Máximo

2.33

Métricas clave

By Trading Economics

Ingresos

4.5M

-112M

Ventas

11M

60M

Margen de beneficio

-186.246

Empleados

838

EBITDA

8.3M

-102M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+363.91% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-124M

821M

Apertura anterior

0.87

Cierre anterior

2.23

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

353 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Iovance Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2025, 23:01 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept 2025, 21:59 UTC

Ganancias

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept 2025, 23:39 UTC

Charlas de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept 2025, 21:00 UTC

Ganancias

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept 2025, 18:43 UTC

Charlas de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept 2025, 18:38 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept 2025, 18:20 UTC

Charlas de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept 2025, 18:14 UTC

Charlas de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept 2025, 17:59 UTC

Charlas de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept 2025, 16:51 UTC

Ganancias

Correct: Exor 1H Net Loss -EUR624M

17 sept 2025, 16:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 16:34 UTC

Charlas de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept 2025, 16:25 UTC

Ganancias

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept 2025, 16:23 UTC

Ganancias

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparación entre iguales

Cambio de precio

Iovance Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

363.91% repunte

Estimación a 12 meses

Media 10.67 USD  363.91%

Máximo 20 USD

Mínimo 1 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Iovance Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

5

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

3.0208 / 3.5Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat